BeStock  
Stocks › Biotechnology › GENB

Generate Biomedicines GENB

US equityMarket cap rank #3024Biotechnology
$9.54 −$0.83 (-8.00%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $9.90 +3.77%
Open$10.06
Prev close$10.37
Day range$9.40 – $10.58
Volume967.9K
Market cap$1.23B
P/E (TTM)–
Dividend yield–

GENB Stock News

Headlines matching Generate Biomedicines or the GENB ticker, most recent first.

  • Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)TipRanks · 9 Sep 2026 · Direct mention
  • Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24Market news · 7 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25Market news · 7 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 PositiveMarket news · 28 Aug 2026 · Direct mention
  • Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 17 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22Market news · 17 Aug 2026 · Direct mention
  • Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market news · 25 Jun 2026 · Direct mention
  • Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)TipRanks · 25 Jun 2026 · Direct mention
  • Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)TipRanks · 15 Jun 2026 · Direct mention
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25 PositiveMarket news · 8 May 2026 · Direct mention
  • Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 8 May 2026 · Direct mention
  • Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 PositiveMarket news · 14 May 2026 · Direct mention
  • H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16Market news · 13 Apr 2026 · Direct mention
  • Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26 PositiveMarket news · 11 Apr 2026 · Direct mention
  • Guggenheim Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $30Market news · 25 Mar 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on GENB.

Sign in to join the discussion.

Scroll to Top